Roth Capital Reiterates Neutral Rating for Acer Therapeutics
ACERDelisted Stock | USD 0.84 0.02 2.33% |
Slightly above 62% of Acer Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Acer Therapeutics suggests that many traders are alarmed regarding Acer Therapeutics' prospects. Acer Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Acer Therapeutics. Many technical investors use Acer Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Acer |
Acer Therapeutics s stock had its neutral rating reissued by Roth Capital in a report issued on Friday, Benzinga reports. They presently have a 1.50 price target on the biopharmaceutical companys stock. Roth Capitals price objective indicates a potential upside of 31.58 percent from the stocks previous close. Separately, Roth Mkm downgraded
Read at thelincolnianonline.com
Acer Therapeutics Fundamental Analysis
We analyze Acer Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acer Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acer Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Acer Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Acer Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acer Therapeutics stock to make a market-neutral strategy. Peer analysis of Acer Therapeutics could also be used in its relative valuation, which is a method of valuing Acer Therapeutics by comparing valuation metrics with similar companies.
Peers
Acer Therapeutics Related Equities
PHGE | Biomx | 18.33 | ||||
BDRX | Biodexa Pharmaceticals | 14.00 | ||||
KTTA | Pasithea Therapeutics | 6.55 | ||||
ATXI | Avenue Therapeutics | 4.37 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
HOTH | Hoth Therapeutics | 1.20 | ||||
NRBO | Neurobo Pharmaceuticals | 0.43 | ||||
LEXX | Lexaria Bioscience | 0.48 | ||||
SABS | SAB Biotherapeutics | 1.02 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
VRAX | Virax Biolabs | 4.83 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |